---
document_datetime: 2025-02-05 10:06:28
document_pages: 24
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/apidra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: apidra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 15.9382838
conversion_datetime: 2025-12-26 17:52:42.789467
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Apidra

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0096               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                   | 04/02/2025                          |                                             | Labelling and PL                 |           |
| II/0095              | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch | 17/10/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |    |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|-----------------------------------|
| N/0094             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 07/08/2024 |     | PL |                                   |
| IA/0093/G          | This was an application for a group of variations. B.I.c.2.c - Change in the specification parameters and/or limits of the immediate packaging of the AS - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.a - Change in the specification parameters and/or limits of the immediate packaging of the AS - | 13/12/2023 | n/a |    |                                   |
| PSUSA/1752/ 202304 | Periodic Safety Update EU Single assessment - insulin glulisine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 30/11/2023 | n/a |    | PRAC Recommendation - maintenance |
| N/0091             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 26/06/2023 |     | PL |                                   |
| IG/1551            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                            | 02/12/2022 | n/a |    |                                   |

<div style=\"page-break-after: always\"></div>

| II/0088/G          | This was an application for a group of variations. B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms   | 10/03/2022   | n/a        |                       |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------|
| N/0089             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                  | 09/12/2021   |            | PL                    |                                   |
| N/0087             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                  | 05/11/2020   | 20/08/2021 | PL                    |                                   |
| PSUSA/1752/ 202004 | Periodic Safety Update EU Single assessment - insulin glulisine                                                                                                                                                                                                                                                                                                                                                                                   | 29/10/2020   | n/a        |                       | PRAC Recommendation - maintenance |
| IG/1282            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                | 15/09/2020   | n/a        |                       |                                   |
| IAIN/0085          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                    | 10/08/2020   | 20/08/2021 | SmPC, Annex II and PL |                                   |
| N/0083             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                  | 24/02/2020   | 20/08/2021 | PL                    |                                   |

<div style=\"page-break-after: always\"></div>

| II/0082/G          | This was an application for a group of variations.                                                                                                                                                                                                                                                                                               | 16/01/2020   | n/a        |                        |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| PSUSA/1752/ 201904 | Periodic Safety Update EU Single assessment - insulin glulisine                                                                                                                                                                                                                                                                                  | 31/10/2019   | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0080          | B.IV.1.b - Change of a measuring or administration device - Deletion of a device                                                                                                                                                                                                                                                                 | 15/02/2019   | 11/04/2019 | SmPC, Labelling and PL |                                   |
| IG/0999/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name | 20/11/2018   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or   |            |     |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/1752/ 201804 | Periodic Safety Update EU Single assessment - insulin glulisine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 31/10/2018 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0077            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                  | 03/04/2018   | 11/04/2019   | SmPC, Labelling and PL   |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| PSUSA/1752/ 201704 | Periodic Safety Update EU Single assessment - insulin glulisine                                                                                                                                                                                                                                                                                                                                                                                 | 26/10/2017   | n/a          |                          | PRAC Recommendation - maintenance |
| IAIN/0075          | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                             | 16/06/2017   | 03/08/2017   | SmPC, Labelling and PL   |                                   |
| II/0074/G          | This was an application for a group of variations. B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms | 09/06/2017   | n/a          |                          |                                   |
| IA/0073            | B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)                                                                                                                                                                                                                                                                                                                                                           | 05/01/2017   | 03/08/2017   | SmPC, Labelling and PL   |                                   |
| IB/0071            | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of                                                                                                                                                                                                                                                    | 14/12/2016   | n/a          |                          |                                   |

<div style=\"page-break-after: always\"></div>

|                    | an obsolete parameter)                                                                                                                                                                                                                                                                                                     |            |            |           |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|-----------------------------------|
| IA/0070/G          | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 14/12/2016 | n/a        |           |                                   |
| IB/0072            | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                               | 06/12/2016 | n/a        |           |                                   |
| PSUSA/1752/ 201604 | Periodic Safety Update EU Single assessment - insulin glulisine                                                                                                                                                                                                                                                            | 27/10/2016 | n/a        |           | PRAC Recommendation - maintenance |
| IB/0069            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                           | 04/10/2016 | n/a        |           |                                   |
| II/0066            | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                              | 15/09/2016 | 03/08/2017 | Labelling |                                   |
| N/0067             | Update of the package leaflet with revised contact details of the local representatives for Hungary, Italy and Lithuania. In addition, the MAH took the opportunity to make linguistic amendments to the                                                                                                                   | 28/06/2016 | 03/08/2017 | PL        |                                   |

<div style=\"page-break-after: always\"></div>

|                    | Danish, Finnish, Hungarian, Icelandic, Lithuanian, Spanish and Swedish labelling and package leaflets. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                              |            |            |    |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| IA/0065/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of | 22/12/2015 | n/a        |    |                                   |
| IB/0064            | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                                                                                                                       | 09/11/2015 | n/a        |    |                                   |
| PSUSA/1752/ 201504 | Periodic Safety Update EU Single assessment - insulin glulisine                                                                                                                                                                                                                                                                                                                                                                                                      | 06/11/2015 | n/a        |    | PRAC Recommendation - maintenance |
| N/0063             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                     | 07/08/2015 | 03/08/2017 | PL |                                   |

<div style=\"page-break-after: always\"></div>

| PSUV/0060   | Periodic Safety Update                                                                                                                                                                                                                                                                         | 06/11/2014   | n/a        |    | PRAC Recommendation - maintenance   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|-------------------------------------|
| IB/0061     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                               | 24/10/2014   | n/a        |    |                                     |
| IB/0057     | B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                              | 22/07/2014   | n/a        |    |                                     |
| IG/0454     | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                | 17/07/2014   | n/a        |    |                                     |
| IG/0453     | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                 | 27/06/2014   | n/a        |    |                                     |
| II/0054     | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 26/06/2014   | n/a        |    |                                     |
| PSUV/0055   | Periodic Safety Update                                                                                                                                                                                                                                                                         | 08/05/2014   | n/a        |    | PRAC Recommendation - maintenance   |
| N/0056      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                               | 06/05/2014   | 01/10/2014 | PL |                                     |

<div style=\"page-break-after: always\"></div>

| IB/0053   | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/11/2013   | 01/10/2014   | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0049   | Update of sections 4.2, 4.4, 4.8 and 6.6 of the SmPC following assessment of Apidra Risk Management Plan, to inform healthcare professionals about the causes leading to diabetic ketoacidosis (DKA) when Apidra is administered in continuous subcutaneous insulin infusions (CSII), and to highlight the advice on how to mitigate the risk by correct use of these systems. The package leaflet has been updated accordingly. The amendments to the product information are only applicable to the Apidra 100 Units/ml solution for injection in a vial, as this is the only presentation that can be used in a pump system. The MAH has also submitted data clarifying the stability of Apidra in pump systems for CSII which was also requested in RMP 025.6. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is being brought in line with the latest QRD template version 9.0. The requested variation proposed amendments to the Summary of Product Characteristics, Annex II and Package Leaflet. | 24/10/2013   | 01/10/2014   | SmPC, Annex II and PL    | Following the assessment of the Apidra Risk Management Plan, the MAH was requested to submit a Type II variation to revise the SmPC and PL to make more prominent the risk of Diabetic Ketoacidosis (DKA) associated with pump administration and to include advice on how to manage the condition. In addition, the MAH was asked to respond to a list of questions on the stability of Apidra in pump systems for with continuous subcutaneous insulin infusions (CSII). The amendments to the product information are only applicable to the Apidra 100 Units/ml solution for injection in a vial, as this is the only presentation that can be used in a pump system. The MAH agreed to amend section 4.4 of the SmPC to include information on the risk of DKA occurring in association with CSII. Additionally the MAH included 'Hyperglycaemia (potentially leading to Diabetic ketoacidosis)' in section 4.8 with a frequency of 'unknown'. The MAH also agreed that advice already in section 6.6 should be included in section 4.2. The package leaflet has been amended to highlight this risk to patients (given that patients will self-administer Apidra using CSII). The updated text in sections 4.2 and 4.4 of the SmPC reads as follows: 4.2 Posology and method of administration Method of administration |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| following the assessment of an USR, class labelling, PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by MAH   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                        | infusion pump therapy must be trained to administer insulin by injection and have alternative insulin delivery system available in case of pump system failure (see section 4.2 and 4.8).   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0052   | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/09/2013 | 01/10/2014 | SmPC, Labelling and PL |                                                                                                                                                                                             |
| IG/0314   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/07/2013 | n/a        |                        |                                                                                                                                                                                             |
| IG/0300   | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 03/05/2013 | n/a        |                        |                                                                                                                                                                                             |
| II/0046/G | This was an application for a group of variations. This was an application for a group of variations to change in the specification parameters and limits of the finished product. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change | 17/01/2013 | 17/01/2013 |                        |                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         | outside the approved specifications limits range                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0047 | Update of section 4.6 of the SmPC in order to reflect current post-marketing experience of Apidra use in pregnancy. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 18/10/2012 | 19/11/2012 | SmPC and PL                      | In this variation the MAH presented a cumulative summary of reports of exposure in pregnancy from the pharmacovigilance safety database up to 16 April 2012. This includes 114 reports of pregnancy exposure reported with or without an adverse event from all sources (spontaneous, clinical trial, and post-marketing surveillance). The limited information provided did not show any new safety concerns. |
| II/0048 | Changes in the manufacturing process of the active substance. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol                                                                                                                                                                  | 20/09/2012 | 20/09/2012 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0044 | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol                                                                                                                                                                                                                                | 24/05/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                |
| WS/0208 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 6.6 for SoloStar pre-filled pen                                                                                                                                                                                                                                      | 15/03/2012 | 20/04/2012 | SmPC, Annex II, Labelling and PL | Update of the labelling documents for three sanofi-aventis insulins is proposed in this type II variation to reinforce the appropriate use of Solostar prefilled pen. This update is based on the experience gained since 2006 (e.g. following reports and questions raised by the pen                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | presentation for the Insuman, Insuman Human Whintrop, Apidra, Lantus and Optisulin to reinforce the appropriate use of SoloStar. The Package Leaflet was proposed to be updated in accordance. Furthermore, the MAH proposed this opportunity to bring the PI in line with latest QRD template version 8.0 for Insuman, Apidra, Lantus and Optisulin. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |     | users) and a continued evaluation of possible improvements of the Product Information. During this period a number of product technical complaints were received concerning the functionality of the pen, namely a blocked pen, where it is impossible to dial or inject a dose. The cause was identified that when dialling a dose and pushing the dose button without a needle attached to the pen, a mechanical pressure within the system builds, leading to a blockage of the pen mechanism. For this reason the Instructions for Use are updated to make the patient aware not to dial a dose or push the dose button without having a needle attached. There was no technical change made to the Solostar prefilled pen.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0147/G | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV                                                                                                                                                                                                                                                                                                                            | 29/02/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|         | to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                               |            |            |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| II/0038 | To change in the specification parameters and limits of the immediate packaging of the finished product. B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation | 16/02/2012 | 16/02/2012 |
| IB/0043 | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)               | 19/12/2011 | n/a        |
| IB/0039 | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)               | 19/10/2011 | n/a        |
| IA/0037 | B.III.2.a.2 - Change of specification(s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                               | 26/09/2011 | n/a        |
| IG/0091 | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                          | 05/07/2011 | n/a        |

<div style=\"page-break-after: always\"></div>

| IA/0036   | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                       | 01/06/2011   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0035   | Changes to the cleaning procedure used for the bioreactor during the manufacturing process of the active substance. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol | 19/05/2011   | 19/05/2011 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0029   | Update of product information to reflect the risk of medication errors (insulin mix-up). C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                   | 16/12/2010   | 24/01/2011 | SmPC, Annex II, Labelling and PL | The portfolio of the MAH contains several different insulins with several insulin delivery devices (IDD), including the re- usable devices (OptiPen Pro and OptiClik) and the device/drug combinations (pre-filled disposable pens OptiSet and SoloStar). The complexity regarding the various insulin treatments used in a single diabetic patient, (i.e. long acting, rapid acting; with the latter needing to be administered multiple times a day) in order to achieve optimal glycaemia control has created a situation wherein product differentiation becomes increasingly important. Adverse events associated with insulins mix-ups, often result in massive overdose of the rapid-acting insulin which may subsequently lead to hypoglycaemia, which if left untreated may be life-threatening, or result in death. In most cases, however, the patients noticed the mistake and took measures to avoid hypoglycaemia, which may explain |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                            |            |     |             | the large number of cases with no AE or non-serious cases. In order to mitigate the risk of medication errors, the MAH has focused its efforts up to now on educational activities to ensure the safe administration of their insulins. The MAH has also focused on differentiation strategies for insulin products to mitigate the potential risk of administering the wrong insulin to a person with diabetes. The product information for all the insulins from this MAH has been updated through the present variation to include warnings on the risk of insulin mix-up. Additionally, the MAH will incorporate changes to the existing insulins packaging. The aim of these changes is to better differentiate the different products and to increase readability for the pharmacist, Health Care Professional or patient in order to reduce potential mix-ups.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0034 | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH | 19/01/2011 | n/a | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0033 | B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)                                      | 20/12/2010 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0032 | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g.                                               | 23/11/2010 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | duplication of line)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |                        |                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|-----------------------|
| IB/0031   | Information (SmPC, L and PL) to include the name of the re-usable pens to be used with the cartridge presentations. B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                          | 19/11/2010 | n/a | SmPC, Labelling and PL | Change in the Product |
| IA/0030   | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a                                                                                                                                                                                                                                                                                                                                                                                         | 17/09/2010 | n/a |                        | Member State          |
| IG/0004/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.h - Changes to an existing pharmacovigilance | 06/05/2010 | n/a | Annex II               |                       |

<div style=\"page-break-after: always\"></div>

|         | system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                             |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                         |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0023  | Annex I_2.(e) Change or addition of a new route of administration                                                                                                               | 22/10/2009 | 14/01/2010 | SmPC, Annex II, Labelling and PL | Please refer to the scientific discussion: Apidra H-557-X-23- AR.                                                                                                                                                                                                                                                                                                       |
| IB/0027 | Change to a test procedure of the immediate packaging of the finished product. IB_27_b_Change to test proc. of immediate packaging - other changes (incl. replacement/addition) | 10/11/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0026 | Change in a test procedure of the finished product IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                           | 10/11/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                         |
| R/0025  | Renewal of the marketing authorisation.                                                                                                                                         | 29/05/2009 | 20/08/2009 | SmPC and PL                      | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit-risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Apidra continues to be favourable. |
| N/0021  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                | 05/03/2009 | n/a        | Labelling                        |                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0022 | IB_38_c_Change in test procedure of finished product - other changes                                                                                                            | 12/02/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IA/0024   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                           | 21/01/2009   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0019   | Update of Summary of Product Characteristics, Labelling and Package Leaflet. Update of Summary of Product Characteristics, Labelling and Package Leaflet                                     | 24/04/2008   | 20/06/2008 | SmPC, Labelling and PL | Update of the Product Information to harmonise the SPC, Labelling and PL of the sanofi-aventis insulin containing products (insuline glargine, insulin glulisine and insulin human). Particularly, the package leaflet has been updated to reflect the results of Readability User Testing. The PL has also been updated to reflect the outcome of the user consultation study performed to demonstrate the readability and usefulness of the PL to patients. |
| II/0017   | Extension of Indication To include use of the product in a paediatric population of 6 years and above based on the results of the paediatric studies HMR1964D/3001 and HMR1964A/1017.        | 24/04/2008   | 20/06/2008 | SmPC, Annex II and PL  | Please refer to the scientific discussion: Apidra H-557-II- 17-AR                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0020   | IB_38_c_Change in test procedure of finished product - other changes                                                                                                                         | 20/02/2008   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0018   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                               | 06/08/2007   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0015   | To update section 5.1 and section 5.2 of the SPC following assessment of the documentation concerning 'MAH Obligation to submit data not yet submitted to the EMEA'. The Package leaflet has | 24/05/2007   | 02/07/2007 | SmPC and PL            | Post approval, the MAH has performed additional clinical pharmacology studies to further characterise time- concentration and time-action profiles for dose- proportionality in exposure and effect, and across a wide                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | been amended to correct a mistake in section 3 and to introduce some improvements in section 4 and in the 'Instructions for Use' for Optiset and SoloStar. In addition, minor changes to the list of local representatives have been introduced. The MAH also took the opportunity to update the Annexes in accordance with the QRD template, version 7.2. Update of Summary of Product Characteristics and Package Leaflet   |            |            |             | range of body mass indices, to explore the effect on endogenous glucose production, and to study the diurnal post-prandial blood glucose profile. An in vitro study was performed to add information on protein binding. These data were submitted in the framework of the \"MAH obligation to submit data not yet submitted to EMEA\". Following the assessment of these data, the CHMP requested the MAH to provide full reports for studies F2003KIN0199, 1019, 1501, 1502, 1505 and synopses of studies 3005 and 3502. The MAH amended sections 5.1 and 5.2 of the SPC, to include some of the results that were considered of special interest for the prescribing physician.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016 | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                               | 21/06/2007 | 25/06/2007 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| N/0014  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                              | 22/03/2007 | n/a        | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0013 | IB_25_a_02_Change to comply with Ph. - compliance with EU Ph. - excipient                                                                                                                                                                                                                                                                                                                                                     | 06/12/2006 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0012 | Update of Summary of Product Characteristics and Package Leaflet of the Optiset presentations to reflect a revision of the Optiset Instructions for Use. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                     | 21/09/2006 | 24/10/2006 | SmPC and PL | After the experience gained from user surveys and outside experts consultation, the MAH has proposed to revise the Optiset Instructions for Use and the Summary of Product Characteristics of the Optiset presentations for Apidra. The MAH has performed a readability test that shows that the revised manual complies with the standard acceptance criteria (80% of participants were able to find the information requested in the PL and instructions for use manual and could show that they understand it).                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| II/0010   | New presentation(s)                                                                                                                                                                                                                                                | 27/07/2006   | 01/09/2006   | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0011   | IB_25_a_02_Change to comply with Ph. - compliance with EU Ph. - excipient                                                                                                                                                                                          | 31/07/2006   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0008   | Modifications to the OptiSet pen and imprinting the name of the insulin on the pen for identification. Change(s) to (an) ancillary medical device(s)                                                                                                               | 23/03/2006   | 05/05/2006   | SmPC, Labelling and PL           | The purpose of the change is to implement a technical improvement to OptiSet in order to prevent mishandling of the pen, and thus to improve the safety of the device particularly when it is wrongly used. In addition, the trade name of the insulin will be printed on the pen, to enable a complete differentiation from other insulins provided with the OptiSet pen. The data provided was adequate and satisfactory and the proposed changes were acceptable. The instructions for use of the pen have been updated accordingly. |
| IA/0009   | IA_01_Change in the name and/or address of the marketing authorisation holder IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) IA_05_Change in the name and/or address of a manufacturer of the finished product | 03/03/2006   | n/a          | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0005   | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                    | 13/10/2005   | 19/10/2005   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| N/0006    | The Marketing Authorisation Holder (MAH) applied for an update of the list of local representatives in the Package Leaflet. Linguistic and typographic corrections were also introduced in the labelling and Package Leaflet.                                      | 16/09/2005   | n/a          | Labelling and PL                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004 | Update of sections 4.2, 4.4 and 6.6 of the Summary of Product Characteristics (SPC), labelling and Package Leaflet (PL) for Apidra (OptiSet presentations). In addition, the term \"international units\" was substituted by \"units\" in the PL of all the presentations. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 26/05/2005 | 04/07/2005 | SmPC, Labelling and PL | This variation concerns the update of sections 4.2, 4.4 and 6.6 of the Summary of Product Characteristics (SPC) for Apidra, to include additional warnings for the use of the OptiSet device and to highlight the most important handling steps for the use of the OptiSet in a more prominent way. These changes include an additional warning statement (in Sections 4.2 and 4.4) that the Instructions for Handling in Section 6.6 should be carefully followed. The handling of OptiSet was updated based on readability test results. Accordingly, the Package Leaflet (PL) has been revised for improved clarity including a revision of the instructions for the use of Apidra (OptiSet presentations). A caution statement has also been added to the outer carton. In addition, the term \"international units\" was substituted by \"units\" in all package leaflets (vial, cartridge, cartridge for OptiClik, OptiSet), in line with the CHMP recommendations and the labelling approved for Apidra. |
| II/0002 | This variation was for the addition of a new presentation: cartridge for Opticlick. The package sizes for this presentation introduced with this variation are: 1, 3, 4, 5, 6, 8, 9 and 10 cartridges. New presentation(s)                                                                                                                         | 17/03/2005 | 13/05/2005 | SmPC, Labelling and PL | The new cartridges are identical to cartridges already authorised for the product and are irreversibly integrated in a disposible module for use with the pen delivery device Opticlick., which has already been approved and is also being used with other centrally authorised products. The quality data provided in support of this variation were satisfactory. A separate Summary of Product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                            |            |            |           | Characteristics (SPC) was developed with specific text for Opticlick in sections 6.5 and 6.6.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|-------------------------------------------------------------------------------------------------|
| II/0001 | Change(s) to container                                                                                                                                                                                                                                                                     | 16/03/2005 | 23/03/2005 |           |                                                                                                 |
| N/0003  | The Marketing Authorisation Holder applied for changes to the labelling to add instructions on the aluminium foil used for sealing the transparent plastic tray containing the cartridge. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 15/03/2005 | n/a        | Labelling |                                                                                                 |